Exercise and GLP-1 RA on Insulin Secretion

Effects of 12 Weeks of Endurance Exercise Training Alone or in Combination With Glucagon Like Peptide 1 Receptor Agonist (GLP-1 RA) Treatment on Insulin Secretory Capacity in Type 2 Diabetes

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04383197

Acronym

EXISECRET

Enrollment

Registered

2020-05-12

Start date

2019-12-10

Completion date

2022-08-31

Last updated

2021-02-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 Diabetes

Keywords

Insulin secretion, Beta cell function

Brief summary

The purpose of this study is to determine the effect of endurance exercise on insulin secretory capacity, alone or in addition to treatment with the glucagon-like-peptide receptor agonist semaglutide, in patients with type 2 diabetes.

Detailed description

The effects of endurance exercise alone or in addition to treatment with glucagon-like- peptide receptor agonists on insulin secretory capacity, will be determined in patients with type 2 diabetes. Included patients will be randomized to either 12 weeks of endurance exercise training 3 times a week or therapeutical treatment with semaglutide for 3 months followed by 12 weeks of endurance exercise training 3 times a week. Insulin secretory capacity will be determined by hyperglycemic clamp method before and after.

Interventions

BEHAVIORALEndurance exercise training

Ergometer cycling at 70 % of VO2 max, 45 minutes, 3 times a week

DRUGSemaglutide

3 months of therapeutic treatment with semaglutide

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

40 Years to 70 Years

Healthy volunteers

Inclusion criteria

* Diagnosed with type 2 diabetes * BMI 28-35 * Moderately preserved insulin secretory capacity (determined by glucagon test)

Exclusion criteria

* Insulin treatment * Hypertension grade 3 * Heart disease * Medical history with pancreatitis * Diagnosed with neuropathy * Excessive alcohol consumption * Any condition that would interfere with the protocol.

Design outcomes

Primary

Measure	Time frame	Description
Insulin secretion	Change from baseline insulin secretion after Exercise intervention(12 weeks).	By hyperglycemic clamp

Secondary

Measure	Time frame	Description
insulin sensitivity	Before and after (2 days) Exercise intervention(12 weeks). Before and after 3 months of therapeutic semaglutide treatment	Derived from hyperglycemic clamp and HOMA-IR
Changes in plasma bone markers	Before and after (2 days) Exercise intervention (12 weeks). Before and after 3 months of therapeutic semaglutide treatment	Changes in baseline CTX, PNIP, Osteocalcin and alkaline phosphatase
Insulin secretion	Before and after (3 days) Exercise intervention (12 weeks). Before and after 3 months of therapeutic semaglutide treatment	By Oral glucose tolerance test
Cardiorespiratory fitness	Before and after (3 days) Exercise intervention (12 weeks). Before and after 3 months of therapeutic semaglutide treatment	Changes in maximal oxygen uptake
Body composition	Before and after (3 days) Exercise intervention (12 weeks). Before and after 3 months of therapeutic semaglutide treatment	By DXA
Glucose homeostasis	Before and after (2 days) Exercise intervention (12 weeks). Before and after 3 months of therapeutic semaglutide treatment	Changes in HbA1c

Countries

Denmark

Contacts

Primary ContactArthur Ingersen, MD

hansai@sund.ku.dk+45 60172697

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 9, 2026